Conclusion
From a global perspective, the safe application of therapeutic strategies to COVID-19 can only be effectively achieved by drug repurposing. In this regard, tetracyclines combine potentially beneficial direct anti-viral activity with anti-inflammatory and immunomodulatory properies, as well as anti-bacterial effect, that can together assist in the therapeutic management of severe cases of COVID-19. Their confirmed benefit in the treatment of ARDS strongly supports the notion that they would be of interest for the treatment COVID-19. In addition, Tetracyclines are safe, well-knownand economically accessible, with doxycycline among the WHO essential medicines. This positions them as excellent therapeutic candidates for the management of COVID-19, particularly in developing countries where successful vaccination programs have yet to be established and access to other therapeutic resources is scarce.